STERIS plc provided revenue guidance for fiscal 2023. For fiscal 2023, constant currency organic revenue growth is now anticipated to be approximately 10%, compared with prior expectations of 11%, reflecting ongoing supply chain challenges and procedure volumes somewhat lighter than anticipated. As reported revenue is expected to increase approximately 9%, reflecting the net impact of acquisitions and divestitures as well as approximately $100 million in anticipated negative impact of foreign currency fluctuations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
218.3 USD | -1.25% |
|
-3.77% | -0.71% |
Jun. 07 | Steris Insider Sold Shares Worth $839,960, According to a Recent SEC Filing | MT |
Jun. 07 | Steris Insider Sold Shares Worth $1,132,535, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.71% | 21.58B | |
-5.81% | 180B | |
-1.63% | 106B | |
-4.14% | 67.55B | |
-6.56% | 46.11B | |
+13.22% | 45.79B | |
+4.23% | 41.61B | |
+19.93% | 31.07B | |
+12.33% | 24.77B | |
-5.36% | 24.27B |
- Stock Market
- Equities
- STE Stock
- News STERIS plc
- STERIS plc Provides Revenue Guidance for Fiscal 2023